Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate

BACKGROUND: In the initial absence of specific reversal agents for factor Xa inhibitors (FXa‐Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered for dabigatran reversal. Still, data on the clinical outcome...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Res Pract Thromb Haemost
Auteurs principaux: Bavalia, Roisin, Abdoellakhan, Rahat, Brinkman, Herm Jan M., Brekelmans, Marjolein P. A., Hamulyák, Eva N., Zuurveld, Marleen, Hutten, Barbara A., Westerweel, Peter E., Olie, Renske H., ten Cate, Hugo, Kruip, Marieke, Middeldorp, Saskia, Meijer, Karina, Coppens, Michiel
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Original Article: Thrombosis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292661/
https://ncbi.nlm.nih.gov/pubmed/32548555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12336
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires